REG - Tristel PLC - Exercise of Share Options and Total Voting Rights

TristelAnnouncement

06/08/2024 15:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240806:nRSF4222Za&default-theme=true

RNS Number : 4222Z  Tristel PLC  06 August 2024

Tristel plc

("Tristel" or the "Company")

 

Exercise of Share Options and Total Voting Rights

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products,
announces that it has issued and allotted a total of 60,500 new ordinary
shares of 1 penny each in the capital of the Company ("Ordinary Shares")
following the exercise of options by employees of the Group.

 

Application has been made to the London Stock Exchange for the 60,500 new
Ordinary Shares to be admitted to trading on AIM ("Admission") and it is
expected that Admission will become effective and trading will commence at
8.00 a.m. on 13 August 2024.

 

Total Voting Rights

 

After Admission, the total number of Ordinary Shares in issue will be
47,614,993 and the total number of voting rights will therefore be 47,614,993.
This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information please contact:

 

 Tristel plc                            Via Walbrook PR
 Paul Swinney, Chief Executive Officer  www.investors.tristel.com (http://www.investors.tristel.com/)
 Liz Dixon, Chief Financial Officer

 Walbrook PR Ltd                        Tel: 020 7933 8780 or tristel@walbrookpr.com
 Paul McManus                           Mob: 07980 541 893
 Charlotte Edgar                        Mob: 07884 664 686

 Cavendish Capital Markets Limited      Tel: 020 7220 0500
 Geoff Nash / Dan Hodkinson / Trisyia Jamaludin (Corporate Finance)
 Sunila de Silva (ECM)

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the
manufacture and supply of products using its unique proprietary chlorine
dioxide (ClO(2)) chemistry. The Company is a market leader in manual
decontamination of medical devices, supplying hospitals under the Tristel
(https://tristel.com/) brand, and under the Cache
(https://thecachecollection.com/) brand provides products for sporicidal
surface disinfection, in a format which is a sustainable alternative to
commonly used pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near
Cambridge, and operates globally employing approximately 250 people across 14
subsidiaries selling into 40 countries.

 

The Company has been listed on the London Stock Exchange's AIM market since
2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit:
https://tristel.com (https://tristel.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPFMITMTJMBBI